Vor Biopharma announced the resignation of board member Dr. Andrew Levin, effective immediately on July 6, 2026, with no disagreement involved. The company appointed Dr. David Zaccardelli to fill the vacancy, effective July 7, 2026. Dr. Zaccardelli, a seasoned pharmaceutical executive with CEO experience at multiple firms, will serve as an independent Class II director and receive standard non-employee director compensation, including a $40,000 annual cash retainer and stock option grants.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding VOR BIOPHARMA INC (VOR)?

Major stakeholders currently include TCG Crossover Management, LLC ($96.5M), Ra Capital Management, L.p. ($96.4M), Fcpm Iii Services B.v. ($73.5M). Based on the latest 13F filings, there are a total of 80 tracked investment funds and institutions maintaining positions in VOR.

What is the overall institutional sentiment toward VOR recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $369.3M, driven by 57 managers accumulating shares while 20 reduced their exposure.

Which institutions have been selling or reducing their VOR positions?

In the latest period, 10 funds trimmed their holdings, and 10 managers completely exited their positions. The aggregate reported sell value was $73.2M.

Are there any notable investors adding VOR to their portfolios?

Yes, buying activity remains notable. 32 institutions opened new positions in {ticker}, and 25 existing holders added to their shares. The total reported buy value for the quarter amounted to $450.1M.